1. 322 Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2). (25th January 2023) Authors: Blauvelt, Andrew; Thyssen, Jacob P; Guttman-Yassky, Emma ; Bieber, Thomas; Carrascosa, Jose Manuel; Simpson, Eric; Rosmarin, David ; Elmaraghy, Hany; Meskimen, Eric; Natalie, Chitra R; Liu, Zhuqing; Xu, Chenjia; Pierce, Evangeline; Morgan-Cox, MaryAnn; Silverberg, Jonathan I Journal: British journal of dermatology Issue: Volume 188(2023)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗